Pfizer Inc. (PFE) CEO Albert Bourla delivered some sharp words at Davos this week, and he wasn't particularly subtle about it. Speaking at a Wall Street Journal event during the World Economic Forum in Switzerland on Wednesday, Bourla called Robert F. Kennedy Jr.'s views on vaccines "anti-science" and made it clear he sees a problem at the top of US health policy.
The issue, according to Bourla, is that conversations with Kennedy go reasonably well until vaccines come up. They've had productive discussions about cancer research and pharmaceutical pricing, but when immunization enters the chat, things fall apart. Bourla described Kennedy's position as rigid and ideological, more like a belief system than something open to scientific debate.
When asked what would need to change for vaccine discussions to actually move forward, Bourla didn't dance around it. His answer: "the health secretary." He didn't elaborate, but the implication was pretty clear—he thinks leadership at the Department of Health and Human Services is the roadblock.
The China Warning
But Bourla wasn't just focused on vaccines. He also took aim at recent funding cuts to US universities under President Trump's administration, warning that these decisions are weakening America's standing in global health research at exactly the wrong time. Why wrong? Because China is moving fast.
Bourla pointed out that elite American institutions like Harvard, MIT, and Stanford used to dominate global health research rankings. Not anymore. According to him, Chinese universities now account for roughly 80% of top-tier positions in the field. That's a massive shift in scientific leadership, and Bourla clearly thinks it should worry people.
He also highlighted how China's pharmaceutical sector is expanding rapidly, driven by reforms to intellectual property protections and a modernized regulatory framework. Those changes have attracted investment and sped up domestic innovation. Chinese drugmakers aren't just churning out generics anymore—they're producing original science that could soon compete with Western pharmaceutical companies.
Bourla called it a "meteoric rise" and said Chinese firms are generating credible innovation and high-quality research. His take on US efforts to slow China down? They're ineffective and misguided.
"You can't stop China. And you shouldn't," Bourla told the Journal. Instead of trying to restrain scientific advances that could benefit global health—including cancer research—he urged Western governments to focus on strengthening their own competitiveness.
It's a pointed message at a moment when political tensions around healthcare policy are running high. Bourla is essentially arguing that infighting over vaccines and cutting research funding are strategic mistakes that leave the US falling behind while China accelerates ahead.
PFE Price Action: Pfizer shares were down 1.93% at $25.60 at the time of publication on Friday.
